Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinosonism

European Journal of Clinical Pharmacology

Volumn 50, Issue 1-2, 1996, Pages 7-18

  Kirollos, C ^a   Charlett, A ^b   Bowes, S G ^a   Purkiss, A G ^a   O'Neill, C J A ^a   Weller, C ^a   Dickins, J ^a   Faulkner, G ^a   Nicholson, P W ^c   Hunt, W B ^d   Dobbs, R J ^a   Dobbs, S M ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Monotherapy; Newly diagnosed elderly; Objective assessment; Parkinsonian; Placebo; Selegiline

Indexed keywords

PLACEBO; SELEGILINE;

AGED; ARTICLE; BODY POSTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; TREATMENT OUTCOME; TREMOR;

AGED; ANTIPARKINSON AGENTS; AROUSAL; DOUBLE-BLIND METHOD; FEMALE; GAIT; HUMANS; HYPOKINESIA; MALE; MUSCLE RIGIDITY; PARKINSON DISEASE; POSTURE; PSYCHOMOTOR PERFORMANCE; RESEARCH DESIGN; SELEGILINE; TREATMENT OUTCOME; TREMOR;

EID: 9244248706     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050062     Document Type: Article

References (82)

1. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn 155:154-164
2. Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP Parkinsonism. J Neurosc Res 30:666-672
3. Salo PT, Tatton WG (1992) Deprenyl reduces the death of motorneurones caused by axotomy. J Neurosc Res 31: 394-400
4. Tariot PN, Cohen RM, Sunderland T, et al. (1987) L-Deprenyl in Alzheimer's disease. Arch Gen Psychiat 44:427-433
5. Mangoni A, Grassi MP, Frattola L, et al. (1991) Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 31:100-107
6. Brandeis R, Sapir M, Kapon Y, Borelli G, Cadel S, Valsecchi B (1991) Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged rats. Pharmac Biochem Behav 39:297-304
7. Calne D, Eisen A (1990) Parkinson's disease, motorneuron disease and Alzheimer's disease: origins and interrelationship. In: (eds) Streifler MB, Korczyn AD, Melamed E, Youdim MBH. Advances in neurology Vol 53. Parkinson's disease: anatomy, pathology and therapy, Raven Press, New York, pp 355-360
8. Calne DB, Eisen A, McGeer E, Spencer P (1986) Alzheimer's disease, Parkinson's disease, and motoneurone disease, abiotrophic interaction between ageing and environment. Lancet ii:1067-1070
9. Knoll J, Dallo J, Yen TT. Striatal dopamine, sexual activity and lifespan (1989) Longevity of rats treated with ( )deprenyl. Life Sci 45:525-531
10. British National Formulary, Number 25 (1993) London: British Medical Association and the Royal Pharmaceutical Society of Great Britain
11. Csanda E, Tárczy M (1983) Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neurol Scand [Suppl 95]:117-122
12. Tetrud JW Langston W (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245: 519-522
13. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321:1364-1371
14. Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH (1991) Selegiline as a primary treatment of Parkinson's disease. Acta Neurol Scand 84 [Suppl 136]:70-72
15. Allain H, Cougnard J, Neukirch H-C, the FSMT members (1991) Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT). Acta Neurol Scand 84 [Suppl 136]:73-78
16. The Parkinson Study Group (1993) Effects of Tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328:176-183
17. Golbe LI (1988) Deprenyl as symptomatic therapy in Parkinson's disease. Clin Neuropharmac 11:387-400
18. Heinonen EH, Rinne UK (1989) Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand 80 [Suppl 126]: 103-111
19. Eisler T, Teräväinen H, Nelson R, et al. (1981) Deprenyl in Parkinson disease. Neurology 31:19-23
20. The Parkinson Study Group (1990) Effect of deprenyl on neuropsychological function in early Parkinson's disease. Ann Neurol 28:297
21. Cohen G (1983) The Pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm [Suppl 19]:89-103
22. Birkmeyer W, Knoll J, Riederer P, Youdim MBH, Hars V, Matron J (1985) Increased life expectancy resulting from addition of L-deprenyl to Mudopar R treatment in Parkinson's disease: a long term study. J Neural Transm 64:113-127
23. Sonsalla PK, Golbe LI (1988) Deprenyl as prophylaxis against Parkinson's disease? Clin Neuropharmac 11:500-511
24. Tetrud JW, Langston JW (1989) MPTP-induced Parkinsonism as a model for Parkinson's disease. Acta Neurol Scand 80 [Suppl 126]:35-40
25. Knoll J (1989) The pharmacology of selegiline ((-)deprenyl). New aspects. Acta Neurol Scand 80 [Suppl 126]:83-91
26. Heinonen EH, Lammintansta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand 84 [Suppl 136]: 44-59
27. Rinne JO, Röyttä M, Paljärvi L, Rummukainen J, Rinne UK (1991) Selegiline (deprenyl) treatment and death of nigral neurones in Parkinson's disease. Neurology 41:859-861
28. Schoenberg BS (1987) Epidemiology of movement disorders. In: Marsden CD, Fahn S (eds) Movement disorders, 2, Butterworth, London pp 17-62
29. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427-442
30. Quinn NP, Hussain FA (1986) Parkinson's disease Br med J 293:379-381
31. Denham MJ, Jefferys P (1984) Modified Tooting Bec questionnaire. In Source book of geriatric assessment, vol 2, Karger Hampshire: p 52
32. Bowes SG, Clark PK, Charlett A, et al. (1991) Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: reliability, sensitivity and specificity of measures of brady- or hypokinesia. Br J Clin Pharmac 31:295-304
33. Webster DD (1959-60) A method of measuring the dynamic characteristics of muscle rigidity, strength, and tremor in the upper extremity. IRE Tans Med Electronics 6-7:159-164
34. Duggan TC, McLellan DL (1973) Measurement of muscle tone: a method suitable for clinical use. Electroencephalography and clin. Neurophysiol 35:654-658
35. Teravainen H, Tsui JKC, Mak E, Calne DB (1989) Optimal indices for testing Parkinsonian rigidity. Can J Neurol Sci 16:180-183
36. Webster DD (1968) Clinical analysis of the disability of Parkinson's disease. Modern Treatments 5:257-282
37. Weller C, Dobbs SM, Dobbs RJ (1991) Landmarks in the development of biotelemetry. Proceedings of the Eleventh International Symposium on Biotelemetry, Uchiyama A, Amlaner CJ (eds) Waseda University Press, Japan, pp 3-8
38. Wright BM (1971) A simple mechanical ataxia-meter. J Physiol (Lond) 218:27-8P
39. Dobbs RJ, Bowes SG, Charlett A, et al. (1993) Hypothesis: the bradyphrenia of parkinsonism is a nosological entity. Acta Neurol Scand 87:255-261
40. Dobbs RJ, Lubel DD, Charlett A, et al. (1992) Hypothesis: age-associated changes in gait represent, in part, a tendency towards parkinsonism. Age Ageing 21:221-225
41. Bowes SG, Charlett A, Dobbs RJ, et al. (1992) Gait in relation to ageing and idiopathic parkinsonism. Scand J Rehab Med 24:181-186
42. Beck AT, Beamesderfer A (1974) Assessment of depression: the depression inventory. In Psychological measurement in psychopharmacology, 7, Pichot T. (ed) Modern problems in pharmacopsychiatry, Karger, Basel:pp151-59
43. Mackay C, Cox T, Burrows G, Lazzerini T (1978) An inventory for the measurement of self-reported stress and arousal. Br J Soc Clin Psychol 17:283-284
44. Weller C, O'Neill CJA, Charlett, A, et al. (1993) Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor. Br J Clin Pharmac 35:379-385
45. Mathews JSN, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. Br Med J 300:230-235
46. Dixon WJ (1990) BMDP statistical software manual, University of California Press, Berkley: pp 1207-1243
47. Altman DG (1991) Practical statistics in medical research. John Wiley, London: pp 371-381
48. Draper NR, Smith H (1981) Applied regression analysis (2nd edition). John Wiley, New York: pp 250-257
49. Royston JP (1982) An extension of Shapiro and Wilk's test for normality to large samples. Appl, Statist 31:115-125
50. Schweder T (1981) A simple test for a set of sums of squares. Appl Statist 30:16-21
51. Kirollos C, Charlett A, Purkiss, AG, et al. (1995) Methodology for objective measurement of activation of rigidity: diagnostic, therapeutic and pathogenetic implications for idiopathic parkinsonism. Br J Clin Pharmacol 39:563-564P.
52. Charlett A., Dobbs RJ, O'Neill CJA, et al. (1995) Objective evaluation, using gait analysis, of potentially therapeutic interventions, in elderly untreated sufferers from idiopathic parkinsonism. Br J Clin Pharmacol 39:569P
53. Kirollos C, O'Neill CJA, Dobbs RJ, et al. (1993) Quantification of the cardinal signs of Parkinsonism and of associated disability in spouses of sufferers. Age Ageing 22: 20-26
54. Weller C, Humphrey SJE, Kirollos C, et al. (1992) (Gait on a shoestring: falls and foot separation in Parkinsonism. Age Ageing 21:242-244
55. Adams JD, Odunze IN (1991) Oxygen free radials and Parkinson's disease. Free Radical Biol Med 10:161-169
56. Hirsch EC, Graybiel AM, Agid Y (1989) Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease. Acta Neurol Scand 80 [Suppl 126]:19-22
57. Fornstedt B, Brun A, Rosengren E, Carlsson A (1989) The apparent autooxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm 1: 279-295
58. Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO (1990) Maintenance of 1-deprenyl prolongs life in aged male rats. Life Sci 47:415-420
59. Reiderer P, Konradi C, Hebenstreit G, Youdim MBH (1989) Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol Scand 80 [Suppl 126]:41-45
60. Oreland L (1991) Monoamine oxidase, dopamine and Parkinson's disease. Acta Neurol Scand 84 [Suppl 136]:60-65
61. Jenner P (1991) Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand 84 [Suppl 136]:6-15
62. Youdim MBH, Ben-Shachar D, Riederer P (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand 80 [Suppl 126]:47-54
63. Tetrud JW, Langston JW (1987) R-(-)-Deprenyl as a possible protective agent in Parkinson's disease. J Neural Transm [Suppl 25]:69-79
64. Parkinson Study Group (1989) DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 46:1052-1060
65. Calne DB, Langston JW (1983) Aetiology of Parkinson's disease. Lancet ii:1457-1459
66. Martttila RJ, Rinne UK (1989) Epidemiological approaches to the aetiology of Parkinson's disease. Acta Neurol Scand 80 [Suppl 126]:13-18
67. Zigmond MJ, Hastings TG, Abercrombie ED (1992) Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease. In: Neurotoxins and neurodegenerative disease, Ann New York Acad Sci 648:71-86
68. O'Neill CJA, Bowes SG, Charlett A, et al. (1994) Siblings of elderly sufferers have a tendency towards idiopathic Parkinsonism: shared xenobiotic exposure or inheritance? Br J Clin Pharmac 37:115P
69. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J (1985) Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquinine. Lancet ii, 1213-1216
70. Armstrong M, Daly AK, Cholerton S, Bateman N, Idle JR (1992) Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 339, 1017-1018
71. Smith CAD, Gough AC, Leigh PN, et al. (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339:1375-1377
72. Williams A, Sturman S, Steventon G, Waring R (1991) Metabolic biomarkers of Parkinson's disease. Acta Neurol Scand 84 [Suppl 136]:19-23
73. Rajput AH, Uitti RJ, Stern W, Laverty W (1986) Early onset of Parkinson's disease in Saskatchewan-environmental considerations for aetiology. Can J Neurol Sci 13:312-316
74. Tanner CM (1989) The role of environmental toxins in the etiology of Parkinson's disease. Trends in Neurosci 12:49-54
75. Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG (1993) Environmental antecedents of young-onset Parkinson's disease. Neurology 43:1150-1158
76. Csanda E, Tárczy M (1997) Selegiline in the early and late phases of Parkinson's disease. J Neural Transm [Suppl 25]: 105-113
77. Yahr MD, Elizan TS, Moros D (1989) Selegiline in the treatment of Parkinson's disease-long term experience. Acta Neurol Scand 80 [Suppl 126]:157-161
78. Goldstein A, Lewis A, Kalman SM (1974) Principles of drug action: the basic pharmacology, 2nd ed. Wiley, London:p586
79. Karoum F, Chuang L-W, Eisler T, et al. (1982) Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. Neurology 32:503-509
80. Przunkek H, Kuhn W (1987) The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. J Neural Transm [Suppl 25]: 97-104
81. Eatough VM, Kempster PA, Frankel JP, et al. (1990) Effects of L-Deprenyl on Parkinsonian bradyphrenia. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds) Advances in neurology, vol 53, Parkinson's disease: anatomy, pathology and therapy. Raven Press, New York: pp 441-443
82. Portin R, Rinne UK (1983) The effect of deprenyl (selegiline) on cognition and emotion in Parkinsonian patients undergoing long-term levodopa treatment. Acta Neurol Scand [Suppl 95]: 135-144